There are 2789 resources available
148P - Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial
Presenter: Paul Cottu
Session: ePoster Display
264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)
Presenter: Sarat Chandarlapaty
Session: ePoster Display
97P - Comparative serum metabolome analysis as a diagnostic tool in concomitant rheumatic and malignant diseases
Presenter: Dorothea Marx
Session: ePoster Display
100P - Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
Presenter: George Demetri
Session: ePoster Display
268P - Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]
Presenter: Andreas Wicki
Session: ePoster Display
103P - Rate of BRCA1/2 pathogenic variants according to family and personal history of cancer in a large cohort of triple-negative breast cancer (TNBC) patients (pts) younger than 60 years of age
Presenter: Stefania Zovato
Session: ePoster Display
104P - Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
Presenter: Jesus Garcia-Foncillas
Session: ePoster Display
157P - Moderate physical activity (MPA) modulates immune system in breast cancer (BC) patients during preoperative chemotherapy: The NEO-RUNNER study
Presenter: Ornella Garrone
Session: ePoster Display
254P - Impact of palbociclib-dose reduction on survival: A retrospective cohort study
Presenter: Maria Luisa Romero Lagures
Session: ePoster Display
256P - PI3K mutation is associated with reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer
Presenter: Keechilat Pavithran
Session: ePoster Display